Evocalcet Market

Evocalcet Market Size, Share & Industry Analysis, By Type (Calcimimetic Agent, Parathyroid Hormone Regulator), By Application (Secondary Hyperparathyroidism, Chronic Kidney Disease–Mineral Bone Disorder, Hemodialysis Management), By Formulation (Oral Tablets, Dispersible Tablets, Extended-Release Formulations), Forecast 2025–2035

The Evocalcet market is projected to grow at a CAGR of 6.7% from 2025 to 2035, driven by the rising prevalence of secondary hyperparathyroidism (SHPT) in patients undergoing chronic hemodialysis. As a next-generation calcimimetic agent, Evocalcet offers a more favorable safety profile with reduced gastrointestinal side effects compared to cinacalcet, making it increasingly preferred in nephrology protocols. Its potent ability to regulate parathyroid hormone (PTH) levels and its compatibility with long-term management of chronic kidney disease–mineral bone disorder (CKD–MBD) further solidify its relevance.

Geographically, Japan dominates the Evocalcet market, being the first country to approve and commercialize the drug for SHPT management in dialysis patients. The Asia-Pacific region, including South Korea and China, is witnessing increasing demand due to rising CKD prevalence and the push for better-tolerated PTH regulators. North America and Europe are anticipated to follow, particularly as real-world evidence and comparative trials expand adoption beyond cinacalcet. Latin America and the Middle East are gradually entering the market through generic partnerships and regional nephrology treatment programs focused on improving the quality of life for end-stage renal disease (ESRD) patients.

The Evocalcet market report represents the gaining traction as a preferred calcimimetic in the management of SHPT, particularly in dialysis-dependent patients. Its clinical advantages over older agents and expanding real-world use support sustained market growth. API suppliers that focus on high-purity synthesis, formulation-specific grade production, and regional regulatory certifications are positioned to benefit from the rising global demand for safe and effective CKD-related hormone therapies.

Seeking Comprehensive Intelligence on Different markets? Get in Touch with our Experts

Report Scope & Segmentation

  1. Introduction
  • Overview of Evocalcet
  • Key Applications & Industry Use Cases
  • Market Scope & Study Objectives
  1. Market Overview
  • Global Market Size & Growth Trends (Historical & Forecast)
  • Market Value & Revenue Analysis
  • Demand-Supply Dynamics
  1. Segmental Outlook
  • By Type
    • Calcimimetic Agent
    • Parathyroid Hormone Regulator
  • By Application
    • Secondary Hyperparathyroidism
    • Chronic Kidney Disease–Mineral Bone Disorder
    • Hemodialysis Management
  • By Formulation
    • Oral Tablets
    • Dispersible Tablets
    • Extended-Release Formulations
  1. Price Analysis
  • Current Price Trends (Per kg & Per Ton)
  • Price Fluctuation Factors (Raw Material Costs, Production, Trade Tariffs)
  • Regional Price Comparison (North America, Europe, Asia-Pacific, and Other)
  1. Production & Supply Volume
  • Global Production Capacity & Key Manufacturers
  • Production Process & Technological Developments
  • Raw Material Analysis
  1. Trade Analysis (Import & Export)
  • Major Exporting & Importing Countries
  • Trade Volume & Value Statistics
  • Impact of Trade Regulations & Policies
  1. Regional Analysis
  • North America (US and Canada)
  • Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, Taiwan, India, and Rest of Asia-Pacific)
  • Rest of the World (Latin America, Middle East, and Africa)
  1. Competitive Landscape
  • Top Global Manufacturers & Market Share
  • Company Profiles & Key Developments
  • Mergers, Acquisitions & Investments
  1. Regulatory & Compliance Factors
  • FDA, REACH, and Other Regulatory Frameworks
  • Environmental & Safety Considerations
  • Emerging Policies Impacting Market Growth
  1. Conclusion & Strategic Recommendations
  • Key Takeaways for Stakeholders
  • Market Entry Strategies
What is Evocalcet?
Evocalcet is a calcimimetic agent used to treat secondary hyperparathyroidism in patients undergoing dialysis for chronic kidney disease. It works by increasing the sensitivity of calcium-sensing receptors on the parathyroid gland, thereby reducing parathyroid hormone levels.
What is the market growth of Evocalcet?
The global Evocalcet market is expected to grow at a CAGR of 6.7% from 2025 to 2035, fueled by a rising prevalence of chronic kidney disease and end-stage renal disease, alongside growing demand for more tolerable and effective treatments for hyperparathyroidism.
What are the drivers of the Evocalcet market?
The key drivers include the increasing dialysis patient population, greater clinical preference for Evocalcet over older calcimimetics due to better gastrointestinal tolerability, and ongoing expansion of nephrology care services across both developed and developing countries.
Who are the key players operating in the Evocalcet market?
Key players include Kyowa Kirin, the original developer and marketer of Evocalcet, along with other pharmaceutical firms aiming to enter the market with generic versions or related renal care products as the drug’s adoption grows globally.
Which region would exhibit the fastest growth in the Evocalcet market?
Asia-Pacific is projected to show the fastest growth in the Evocalcet market during 2025–2035 due to the high incidence of chronic kidney disease, increasing dialysis penetration, healthcare policy reforms, and strong pharmaceutical market expansion in countries like Japan, China, and India.
$1800/- Single User License
$3600/- Multi User License

How can we help you?

Reach out to discuss how our team can help your business achieve real results.